Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

Summary

Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free survival at 1 yr from initiation of treatment.

Timeline

Start

2016-05-11

Primary completion

2016-09-20

Completion

2017-09-14

Outcome

Outcome not reported

Stopped: “Study team felt toxicity of study regimen outweighed potential benefit.”

Drugs

Indications